From Arsenic to Biologicals: A 200 Year History of PsoriasisPsoriasis is an ancient disease that was probably first described by Hippocrates more than 400 years BC. In the Middle Ages, psoriasis was confused with leprosy, a situation that lasted until the beginning of the 19th century when psoriasis was finally recognised as being a specific clinical entity. From Arsenic to Biologicals: A 200 year History of Psoriasis is a chronological description of how the unravelling of the mechanisms underlying psoriasis have led to a change from the empirical "try it and see" treatments of the 19th and early 20th centuries to the evidence-based treatments of the present day. The book describes the various theories proposed to explain psoriasis and the introduction of new treatments, decade by decade, throughout the 20th century. These range from the belief that psoriasis resulted from an internal metabolic disturbance in the 19th century, when arsenic was the systemic treatment of choice, through to the 21st century when the recognition that psoriasis was a disease of the immune system enabled the development and use of therapeutic biological agents. This book would be of interest to individuals with psoriasis, dermatologists or skin researchers, or anyone studying the history of medicine. |
Contents
Recognition of psoriasis as a specific disease | 1 |
Causes and treatments of psoriasis in the 19th Century | 7 |
1900 1930 | 23 |
Chapter4 The 1930s | 33 |
Prewar Germany and World War II | 41 |
The 1950s | 47 |
The 1960s | 57 |
The 1970s | 63 |
The 1980s | 77 |
The 1990s | 87 |
Psoriasis in literature and the media | 101 |
The 21st Century and the Future | 107 |
References | 117 |
Common terms and phrases
19th century acid activated addition agents antibodies antigens appeared applied approach arsenic arthritis associated became began beginning blood cAMP carried caused CD4+ T cells century changes Chapter chronic chrysarobin Class clear clinical common consistent cytokines decade defect demonstrated Dermatol dermatologists described different doses drug effects epidermal cell evidence expression extract factors families findings first followed function further Furthermore genes genetic growth human hypothesis immune improvement increased individuals induced infection inhibit initial involved keratinocytes known later layer less levels London lymphocytes major mechanism nature normal observed possible present probably production proliferation proposed protein psoriasis patients psoriatic skin lesions published receptor recognised reduced remained reported resolution response result role showed side effects skin diseases specific stimulated streptococcal studies subsequently success suggested systemic therapeutic therapy topical treat treat psoriasis treatment treatment of psoriasis types various vitamin whilst